Generalized Anxiety Disorder: Diagnostic and Management Protocol
Diagnostic Criteria and Screening
Use the GAD-7 scale as your primary screening tool, with a cutoff score of ≥9 points indicating a positive screen for generalized anxiety disorder 1. The GAD-2 (first two questions only) can serve as an ultra-short screening tool, with ≥3 points warranting full GAD-7 assessment 1.
Core Diagnostic Features
The pathognomonic symptom of GAD is multiple excessive worries that may present as disproportionate concerns or fears 2. Critically, patients with GAD worry about a range of topics beyond a single issue—not just one area of life 2. The worry must be:
- Excessive and difficult to control
- Present for most days over at least 6 months
- Associated with functional impairment in home, relationships, social, or occupational domains 2
Presenting Symptoms
Physical symptoms that commonly bring GAD patients to primary care include 2, 1:
- Restlessness or feeling on edge
- Muscle tension (often presenting as headaches or body aches)
- Fatigue
- Difficulty concentrating
- Irritability
- Sleep disturbances
- Trembling, sweating, tachypnea, tachycardia, palpitations 2
Common pitfall: Patients with GAD frequently present with somatic complaints without explicitly reporting anxiety symptoms 3. They may seek care for headaches, noncardiac chest pain, fatigue, insomnia, or abdominal discomfort without recognizing these as anxiety-related 3.
Gastrointestinal Manifestations
Gastrointestinal symptoms are prominent in GAD and represent a critical bidirectional relationship 4, 5. GI symptoms include:
- Abdominal discomfort or pain
- Gastrointestinal distress (nausea, bloating)
- Altered bowel habits
- Functional GI symptoms mimicking IBS 6
The gut-brain axis dysfunction underlies this connection, involving nervous, endocrine, and immune system dysregulation 5. The prevalence of anxiety disorders among patients with functional GI disorders is substantially higher than in the general population 5. Conversely, GI symptoms are more prevalent in individuals with anxiety disorders, creating a self-perpetuating cycle.
Key Clinical Point
When patients present with chronic GI complaints without clear organic pathology, actively screen for GAD using the GAD-7 7. Medical and substance-induced causes of anxiety must be ruled out before finalizing the diagnosis 2.
Management Protocol
Step 1: Severity Assessment and Referral Thresholds
After positive GAD-7 screening (≥9 points):
- Moderate to severe symptoms (GAD-7 ≥15) OR any score with suicidal ideation, severe agitation, psychosis, or risk of harm: Immediate referral to psychiatrist or psychologist 2
- Moderate symptoms (GAD-7 10-14) without red flags: Can initiate treatment in primary care with close monitoring
- Assess for comorbid depression using PHQ-9, as GAD commonly co-occurs with mood disorders 2
Step 2: First-Line Treatment Selection
Cognitive Behavioral Therapy (CBT) and pharmacotherapy with SSRIs or SNRIs are equally effective first-line treatments 8, 9. The combination of CBT plus medication offers superior outcomes compared to either alone 6.
Pharmacotherapy Algorithm:
For GAD with predominantly psychological symptoms:
- Start SSRI (sertraline 25-50 mg daily, fluoxetine 10-20 mg daily, or escitalopram 10 mg daily) 6, 9
- Titrate weekly based on response and tolerability
- Target therapeutic doses within 4-6 weeks
For GAD with prominent GI symptoms:
- Consider low-dose tricyclic antidepressants (TCAs) as they address both anxiety and GI symptoms, particularly abdominal pain 7
- Start amitriptyline 10-25 mg at bedtime or nortriptyline 10-25 mg daily
- However, if moderate-to-severe mood symptoms coexist, prioritize SSRIs at therapeutic doses over low-dose TCAs, as low doses won't adequately treat the mood disorder 7
For refractory cases:
- SNRIs (venlafaxine extended-release 37.5-75 mg daily) are effective for both anxiety and chronic pain conditions 7, 3
Critical warning: Benzodiazepines are NOT recommended for first-line or long-term treatment due to cognitive impairment, abuse potential, dependence risk, and increased mortality 9. They may be used only for short-term crisis management (2-4 weeks maximum) while initiating definitive therapy.
Psychotherapy:
CBT is the gold-standard psychotherapy 8, 10, 9. For patients with prominent GI symptoms, gut-directed hypnotherapy and mindfulness-based stress reduction (MBSR) show particular efficacy 7, 5.
Step 3: Addressing Comorbid GI Symptoms
When GAD presents with significant GI complaints:
Dietary interventions:
- For moderate-to-severe GI symptoms without eating pathology: Low FODMAP diet delivered by a dietitian 7
- For GAD with mild-to-moderate GI symptoms: Mediterranean diet, which has emerging evidence for both anxiety reduction and gut health 7
- For psychological-predominant symptoms: Mediterranean diet as first choice 7
Microbiome modulation:
- Probiotics may provide adjunctive benefit through gut-brain axis modulation 5
Neuromodulators for GI symptoms:
- As outlined above, low-dose TCAs for pain-predominant symptoms
- SSRIs at therapeutic doses if mood disorder is present 7
Step 4: Monitoring and Duration
- Continue medication for approximately 1 year following symptom remission 6
- Monitor for treatment-emergent adverse events: headaches, GI upset, behavioral activation, worsening anxiety, suicidal ideation 6
- Discontinue during low-stress periods; if symptoms return, strongly consider medication re-initiation 6
- Track progress using GAD-7 scores at regular intervals
Step 5: Integrated Care Approach
For optimal outcomes, combine pharmacotherapy, psychotherapy, lifestyle modifications, and when indicated, dietary interventions 5. This multidisciplinary approach addresses the bidirectional brain-gut axis dysfunction and provides comprehensive symptom management.
Self-management strategies to recommend:
- Regular physical activity (evidence supports anxiety reduction) 7, 9
- Sleep hygiene optimization
- Mindful eating practices
- Stress reduction techniques 7
Common Diagnostic Pitfalls
Missing GAD in patients with chronic somatic complaints: Always screen with GAD-7 when patients present with unexplained physical symptoms, particularly GI complaints 3
Confusing GAD with adjustment disorder: GAD can manifest without identifiable stressors, whereas adjustment disorder requires a clear precipitant 3
Overlooking comorbid substance use: Substance use disorders frequently co-occur and must be treated concurrently 9
Failing to assess functional impairment: Diagnosis requires documented impairment in daily functioning, not just symptom presence 2, 11
Underestimating the GI-anxiety connection: The bidirectional relationship means treating one condition often requires addressing both 5